LAVAL, QC, July 6, 2012 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or
the "Company") held its 2012 Annual General Meeting of Shareholders.
President and Chief Executive Officer Dr. Lise Hébert provided
shareholders the renewed vision on the Company's innovative biophotonic
technology and the strategic focus in advancing its therapeutic
programs to treat important unmet needs in tissue repair, dermatology
and dentistry while leveraging the value of the existing commercial
"Over the past 12 months, the Company has refocused its activities and
resources into a two-pronged strategy: first to focus on its two
development programs to significantly advance the clinical trials in
the fields of acne vulgaris and non-healing chronic pressure sores.
Additionally, while successfully growing its revenues KLOX has
undertaken steps to maximize the value of its aesthetic products in the
whitening and rejuvenation arenas and is now in advanced discussions,"
said Dr. Lise Hébert. "Our human and financial resources are now
aligned with our primary goals to set new standards in healthcare and
creating long term value."
KLOX Technologies: Leveraging light-based technologies
KLOX Technologies is focused on the development and commercialization of
a unique, non-invasive technology using a multiple LED lighting system
that interacts with an oxygen-rich gel containing light-trapping
Today, KLOX's cosmetics and medical devices are destined for the rapidly
growing aesthetics, dental, dermatological and tissue repair markets.
Tissue Repair Program:
KLOX is developing WH-1, an innovative light-based treatment for the
multi-billion dollar tissue repair market. During the year, the Company
advanced its program as follows:
Initiated two 15-patient investigator-based case studies in Europe to
document the safety and preliminary efficacy profiles in patients
suffering from Grade II and III pressure sores. The first study is well
advanced and the second one was approved in June 2012 to start this
summer. The safety and preliminary efficacy data are both promising.
Filed the documentation and has requested to meet with the U.S. Food and
Drug Administration along with Health Canada to discuss its
Investigational Device Exemption towards initiating a feasibility study
to investigate the treatment of Grade II pressure sores. The meetings
are expected to take place this summer.
Preparing to file for a registration trial in Europe in the fourth
quarter of this year to study the safety and efficacy of WH-1 in Grade
III chronic pressure sores.
In the dermatology segment, KLOX has developed:
A promising Acne treatment system, AC-1, which is currently in a final
registration trial towards a Class IIa medical device in Europe. The
Company initiated this prospective clinical trial to evaluate the
efficacy and safety of the KLOX biophotonic system on
moderate-to-severe acne in early 2012. Treatment protocol dictated that
only one hemiface of each patient would be treated against a control
segment being the untreated hemiface. Patient recruitment is expected
to be completed this month. Data is expected in the fourth quarter of
2012 with the subsequent filing towards approval in Q1:2013.
A subsequent extension clinical trial that has been approved this month
to treat the other hemiface of the participating patients as well as
investigating safety and persistence of outcomes over an additional
three (3) month period.
KLOX's skin rejuvenation product SKR-1 has cleared the regulatory paths
in Canada, the U.S. and Europe and is ready to be fully commercialized
and marketed across those geographies. KLOX is in advanced discussions
to globally partner this program.
Three important factors in our field of aesthetic dentistry led the
Company to pursue strategic partnering activities on the global front
for its whitening products:
KLOX has significantly increased revenue growth of its professional
Fast&Mild+™ 1 and over-the-counter (OTC) LifeSmile™ 2 whitening products - both positioned to rapidly take a strong foothold
in the professional and OTC teeth whitening markets.
A new European regulation issued in 2011 that all cosmetic whitening
systems that contain greater than 6% hydrogen peroxide will be banned
from the European Union as early as in Fall 2012 3.
KLOX's efficient and unique response to the challenge: irrespective of
the low peroxide content proposed to be allowed in Europe, the Company
created a NEW formulation based on the unique properties of its
biophotonic technology, without hydrogen peroxide. This NEW product is
characterized by increased gentleness and the same efficacy profile as
its Fast&Mild™ professional kit.
The Company is presently considering strategic alternatives to realize
the value of its aesthetic dentistry products.
KLOX provided shareholders with a review and an update on its financial
position along with the financial results of the Company.
KLOX has successfully raised private placement financings totaling $7.25
Strong Management and Sponsorship
Headquartered in Laval, Canada, KLOX Technologies is a private company
chaired by Dr. Francesco Bellini and managed by a group of seasoned
executives and advisors with extensive experience bringing medical
products to market. The board of directors is composed of a
multidisciplinary team of entrepreneurs and scientists with extensive
Board of Directors
KLOX also announced that Dr. Harry Baikowitz is being proposed for
nomination to the Board of Directors subject to the approvals required.
Dr. Baikowitz is expected to be joining Dr. Francesco Bellini,
Chairman, Mr. Carlo Bellini, Mr. Jean Lamarre, Ms. Cesilde Spalvieri
and Dr. Giovanni Scapagnini on the Company's Board of Directors.
1 For more information, go to http://www.fastandmild.com/en/home.html.
2 For more information, go to http://www.lifesmilepen.com/en/home.html
3 http://www.obelis.net/news/new-eu-directive-regarding-tooth-whitening-products/ Annex III, Part I of the Cosmetics Directive, 76/768/EEC
SOURCE KLOX TECHNOLOGY
For further information:
Business, Consumer and Marketing Media:
NATIONAL Public Relations
+1 (514) 843-2313